High-dose interleukin-2 (HD IL-2) continues to have a favorable safety profile compared with data in the original package insert.
Researchers are enrolling patients for part 2 of a phase 2 trial to compare dalantercept plus axitinib for treatment of renal cell carcinoma (RCC).
There are various emerging targeted therapies in renal cell carcinoma (RCC), including cabozantinib, dalantercept plus axitinib.
Final overall survival results of the RECORD-3 trial are consistent with results and support the standard sequence of sunitinib followed by everolimus.
Axitinib treatment may result in higher drug costs compared with everolimus.
A phase 2 trial is enrolling patients with renal cell carcinoma (mRCC) to compare the combination of axitinib plus TRC105 with axitinib alone.
Axitinib initiated at 5 mg twice daily resulted in toleration of higher daily doses with sustained efficacy in patients with metastatic renal cell carcinoma (mRCC).
Similar Outcomes with Everolimus as Second Targeted Therapy for aRCC After Pazopanib or Sunitinib/Sorafenib
Clinical outcomes with everolimus as a second targeted therapy were not significantly different in advanced renal cell carcinoma (aRCC).
A large percentage of real-world patients with metastatic renal cell carcinoma (mRCC) initially deferred systemic therapy.
Side effects with immunotherapy are different from, and in most cases of PD-1 inhibition, better than chemotherapy.
Differing opinions on initial therapy for patients with metastatic renal cell carcinoma (mRCC).
In a population-based setting, sunitinib and pazopanib have similar efficacy in first-line treatment of metastatic renal cell carcinoma (mRCC).
Patients with clear cell renal cell carcinoma who experience RECIST-defined disease progression may be able to safely continue nivolumab treatment.
Clinical benefit and patient characteristics were common reasons for initial systemic therapy for patients with metastatic renal cell carcinoma (mRCC).
Third-line targeted therapy has demonstrated activity and should be offered to clinically eligible patients with metastatic renal cell carcinoma (mRCC).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Warns 14 Companies To Stop Selling Illegal Cancer Treatments
- ASCO Releases Opinion on Hormonal Therapy for Castrate-resistant Prostate Cancer
- Bladder Cancer: Immunotherapies, Combination Therapies, and Current Research
- Pembrolizumab for Advanced Melanoma: Efficacy and Toxicity
- Nivolumab Fails as Single-agent Treatment for Advanced Uterine Leiomyosarcoma